Gonadotropin-releasing-hormone-receptor antagonists

Lancet

Volumn 358, Issue 9295, 2001, Pages 1793-1803

  Huirne, Judith A F ^a   Lambalk, Cornelis B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; CENTRORELIX; CETRORELIX; FOLLITROPIN; GANIRELIX; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; ITURELIX; LUTEINIZING HORMONE; RECEPTOR BLOCKING AGENT; TEVERELIX; UNCLASSIFIED DRUG;

BREAST CARCINOMA; CASTRATION; DESENSITIZATION; ENDOMETRIOSIS; GONAD; HORMONE DEPENDENCE; HUMAN; HYPOPHYSIS FUNCTION; LEIOMYOMA; LUTEINIZATION; OOCYTE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PUBERTY; REPRODUCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035944837     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06797-6     Document Type: Review

References (120)

1. Gonadotropin-releasing hormone and its analogs
2. Primary structure and function of three gonadotropin-releasing hormones, including a novel form, from an ancient teleost, herring
3. Local regulation of gonadotroph function by pituitary gonadotropin-releasing hormone
4. Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium
5. Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro
6. Regulation of human gonadotropin-releasing hormone receptor gene expression in placental cells
7. Human LHRH gene is located on short arm of chromosome 8 (region 8p 11.2-p21)
8. Second gene for gonadotropin-releasing hormone in humans
9. Molecular mechanisms of ligand interaction with the gonadotropin- releasing hormone receptor
10. Sequence alignment of the G-protein coupled receptor superfamily
11. Mapping of the gonadotropin-releasing hormone (GnRH) receptor gene to human chromosome 4q21.2 by fluorescence in situ hybridization
12. A novel mammalian receptor for the evalutionarily conserved type II GnRH
13. 409
14. Gonadotropin-releasing hormone receptors: Structure and signal transduction pathways
15. Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines
16. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells
17. Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone in human granulosa-luteal cells
18. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates
19. 6 in the ligand and extracellular loop two of the receptor as determinants
20. LHRH antagonists
21. Lutenizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis
22. An overview of GnRH antagonist development: Two decades of progress
23. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects
24. Antide and related antagonists of luteinizing hormone release with long action and oral activity
25. Gonadotropin-releasing hormone antagonists with N omega- triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6
26. Potent gonadotropin releasing hormone antagonists with low histamine- releasing activity
27. Abarelix depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: Differential effects on follicle-stimulating hormone
28. Development of GnRH antagonists for prostate cancer: New approaches to treatment
29. Antarelix (EP 24332) a novel water soluble LHRH antagonist
30. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: An overview
31. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist cetrorelix in healthy female volunteers
32. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran): Parts I and II
33. Seven-day administration of the gonadotropin-releasing hormone antagonist cetrorelix in normal cycling women
34. Abarelix-depot (A-D), a potent GnRH pure antagonist in patients (pts) with prostate cancer (PrCA): Initial clinical results and endocrine comparison with superagonists Lupron (L) and Zoladex (Z)
35. Abarelix depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: Differential effects on folicle-stimulating hormone
36. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer
37. Disappearance of endogenous luteinizing hormone is prolonged in postmenopausal women
38. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (ganirelix) with minimal histamine-releasing properties: Studies in postmenopausal women
39. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, cetrorelix (SB-75)
40. Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (ganirelix) administered by intranasal spray
41. Decreased release of gonadotropin-releasing hormone during the preovulatory midcycle luteinizing hormone surge in normal women
42. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (cetrorelix) postpones the luteinizing hormone (LH) surge: Further evidence for the role of GnRH during the LH surge
43. Follicular arrest during the midfollicular phase of the menstrual cycle: A gonadotropin-releasing hormone antagonist imposed follicular-follicular transition
44. Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle
45. Effects of gonadotrophin releasing hormone antagonist and agonist on the pulsatile release of gonadotrophins and alpha-subunit in postmenopausal women
46. Potent pituitary-gonadal axis suppression and extremely low anaphylactoid activity of a new gonadotropin releasing hormone (GnRH) receptor antagonist "azaline B"
47. Cetrorelix, LHRH antagonist
48. Ganirelix acetate, GnRH antagonist treatment of female infertility
49. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: Agonists and antagonists
50. Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin
51. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial
52. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing controlled ovarian hyperstimulation
53. Efficacy and safety of ganirelix acetate (Antagon/Orgalutran) versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation
54. Controlled ovarian hyperstimulation in assisted reproduction: Effect on the immune system
55. Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles
56. Direct ovarian effects and safety aspects of GnRH agonists and antagonists
57. Embryo implantation and GnRH antagonists: Embryo implantation: The Rubicon for GnRH antagonists
58. Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor
59. Effect of the gonadotropin-releasing hormone antagonist ganirelix on cyclic adenosine monophosphate accumulation of human granulosa-lutein cells
60. Embryo implantation and GnRH antagonists: Ovarian action of GnRH antagonists
61. The role of gonadotropin-releasing hormone in murine preimplantation embryonic development
62. Gonadotropin-releasing hormone increases cleavage rates of bovine oocytes fertilized in vitro
63. Gonadotrophin-releasing hormone antagonists inhibit sperm binding to the human zona pellucida
64. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)
65. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
66. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles
67. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon)
68. Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone releasing hormone antagonist cetrorelix
69. Time to revolutionize ovarian stimulation
70. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: A prospective, randomized, double-blind, placebo-controlled study
71. Teducing the risk of multiple births by transfer of two embryos after in vitro fertilization
72. The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg
73. Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation
74. GnRH antagonist in assisted reproduction
75. Cetrorelix levels in plasma and follicular fluid
76. Neonatal outcome of pregnancies established after treatment with recombinant FSH and Ganirelix for ART
77. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility
78. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation
79. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: Preliminary report: Short communication
80. A pilot study involving minimal ovarian stimulation for in vitro fertilization: Extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix
81. GnRH antagonist in single-dose applications
82. An open label multicentre randomised parallel controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and an FNRH-antagonist in patients undergoing an ART(IVF/ICSI)-treatment
83. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization
84. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: Assessment of neuroendocrine and androgen dynamics
85. New trends in combined use of gonadotropin-releasing hormone antagonists with gonadotropins or pulsatile gonadotropin-releasing hormone in ovulation induction and assisted reproductive technologies
86. The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation
87. Initial safety profile and hormonal dose-response characteristics of the pure GnRH antagonist, abarelix-depot, in women with endometriosis
88. Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix
89. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist cetrorelix
90. Gonadotrophin-releasing hormone antagonists: Application in ovary-stimulating and sex-steroid dependent disorders
91. Primary and salvage therapy with LH-RH analogues in ovarian cancer
92. LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer
93. Hormonal treatment of endometrial cancer
94. Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro
95. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary
96. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists
97. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist
98. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia
99. Treatment of patients with advanced prostate cancer with LHRH antagonist cetrorelix
100. Abarelix-depot (A-D) versus leuprolide acetate (L) for prostate cancer: Results of a multi-institutional, randomized, phase III study in 271 patients
101. Abarelix-depot (A-D), a sustained-release (SR) formulation of a potent GnRH pure antagonist in patients with prostate cancer (PrCA): Phase II clinical results and endocrine comparison with superagonist Lupron (L) and Zoladex (Z)
102. Luteinizing hormone-releasing hormone antagonist in prostate cancer
103. Avoidance of FSH surge and maintained suppression of follicle-stimulating-hormone (FSH) with Abarelix depot (A-D) compared to leuprolide (L) ± Bicalutamide in prostate cancer (PC) patients
104. Greater and more rapid decrease in prostate specific antigen (PSA) and testosterone (T) levels with abarelix depot (A-D) compared to leuprolide acetate (L): Results of a multicenter 24-weeks safety study
105. Hormone refractory prostate cancer cells express functional follicle-stimulating hormone receptor
106. Abarelix depot (A-D) a GnRH angagonist benefits highly symptomatic prostate cancer (PC) patients who are at risk for a clinical flare phenomenon with LHRH agonist treatment
107. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone
108. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido
109. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model
110. Randomized controlled trial of three years growth hormone and gonadotropin releasing hormone analog treatment in children with idiopathic short stature and intra uterine growth retardation
111. Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist
112. Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas
113. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys
114. Is radiation-induced ovarian failute in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonists?: Preliminary observations
115. Pharmacologic treatment of hypersexuality and paraphilias in nursing home residents
116. Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity
117. Pharmacokinetics of abarelix depot-F by subcutaneous injection in women with endometriosis associated pain
118. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix (SB-75) in normal men
119. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women